Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
39.68
+1.19 (+3.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
Next >
3 Biotech Stocks to Sell in October
September 29, 2022
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.
Via
InvestorPlace
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
September 29, 2022
Patients didn't show any improvements in a study meant to test multiple drugs.
Via
Investor's Business Daily
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
September 23, 2022
Though successful in early testing, it wasn't enough to win a Phase 3 study.
Via
Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
September 23, 2022
Via
Benzinga
There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
September 09, 2022
Via
Benzinga
Analyst Ratings for Ionis Pharmaceuticals
September 09, 2022
Over the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs
September 07, 2022
Via
Benzinga
Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss
August 09, 2022
The guidance stayed intact despite a wide second-quarter flop.
Via
Investor's Business Daily
Where Ionis Pharmaceuticals Stands With Analysts
July 26, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ionis Pharmaceuticals: Q2 Earnings Insights
August 09, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Moderna, PayPal And Some Other Big Gainers From Wednesday
August 04, 2022
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
August 04, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Via
Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
August 03, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 29, 2022
Good morning, trader! It's time to start off Friday with a breakdown of the biggest pre-market stock movers traders need to know about!
Via
InvestorPlace
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
July 28, 2022
Via
Benzinga
Ionis Reveals Positive Results From Anti-Blood Clot Therapy In Hemodialysis
July 28, 2022
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive topline results of the Phase 2b clinical trial of fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis.
Via
Benzinga
FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review
July 26, 2022
The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis...
Via
Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
July 20, 2022
Via
Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
July 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead
July 06, 2022
As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSYS)...
Via
Benzinga
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
June 30, 2022
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
June 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
June 21, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.